Vitae Biomedical Co., Ltd. is advancing its international clinical validation efforts through engagement with leading medical research institutions in Lithuania, focusing on cross-population evaluation of its urine-based lung cancer detection technology.

During Life Sciences Baltics 2025, the company initiated in-depth discussions with National Cancer Institute and Vilnius University Hospital Santaros Klinikos to explore potential collaboration on multi-ethnic clinical studies. The discussions covered study design, data integration between Asian and European populations, and approaches to validating diagnostic performance across diverse patient groups.

These efforts aim to establish a robust clinical evidence base that supports the applicability of urine-based molecular diagnostics beyond a single population. By expanding validation into European cohorts, Vitae Biomedical seeks to strengthen confidence in the accuracy and clinical utility of its technology across different genetic and environmental backgrounds.

Both sides reached a preliminary alignment to further develop collaboration frameworks, positioning this engagement as a starting point for long-term partnerships in precision medicine and cancer screening.

According to Vitae Biomedical, the initiative represents an important step toward global clinical adoption. The company will continue to advance cross-border validation and real-world implementation of its urine-based detection platform, reinforcing its commitment to enabling non-invasive and accessible early cancer detection worldwide.